Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.

Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine. Real-world analysis of folate ...

Add Yahoo as a preferred source to see more of our stories on Google. As treatment sequencing in ovarian cancer (OC) continues to evolve, an increasing proportion of patients acquire ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers. BRCA2, a crucial player in the body's DNA repair system, aids in repairing damaged DNA.

Survival outcomes for ovarian cancer patients in the post–poly ADP-ribose polymerase inhibitor (PARPi) era in the US. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.